Biopsy Device Market Projected to Reach USD 2.83 Billion by 2031

Healthcare systems are increasingly prioritizing early cancer detection, pushing hospitals and specialized diagnostic centers to adopt more sophisticated tissue-sampling instruments. The shift toward precision medicine has accelerated demand for vacuum-assisted biopsy systems and improved needle-based designs, which allow for more accurate sampling of breast, lung, prostate, and colorectal tissues. Manufacturers are responding by embedding robotic navigation and artificial intelligence into their platforms to enhance targeting and procedural workflows.

Geographically, North America remains the dominant sector due to its established infrastructure and high adoption rates of oncology screening programs. However, the Asia-Pacific region is emerging as a significant growth engine. Countries such as China, Japan, and India are rapidly modernizing their healthcare capabilities, which is driving consistent investment in diagnostic hardware. While technological integration and outpatient care expansion offer substantial opportunities, market players must continue to navigate challenges related to equipment costs, clinician training, and varying access to healthcare across different global markets.